COLUMBIA, Md., Sept. 2 /PRNewswire/ -- ACell, Inc. is announcing its participation at Rodman & Renshaw's 2009 Annual Global Investment Conference.
The conference will be held September 9, 2009 through September 11, 2009 at the New York Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer and President, is scheduled to make an investor presentation on September 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The presentation is expected to take approximately 25 minutes. Investors and strategic partners interested in ACell's proprietary technology are encouraged to contact the company for private one on one discussion while attending the conference.
Mr. DeFrancesco's presentation will provide an update on ACell's regenerative medicine technology and share clinical results of recently completed cases. ACell introduced its wound care devices utilizing a major marketing partner last January. Now, with the recent release of several new extracellular matrix (ECM) surgical devices, ACell is targeting the US plastic surgery, hernia and trauma markets. Several orthopedic products are scheduled for release next year. The company has recently received significant media coverage for the involvement of its MatriStem((R)) MicroMatrix(TM) in re-growing severed fingertips.
ACell is a private company with multiple US and international patents for its proprietary UBM (Urinary Bladder Matrix) ECM technology. ACell's advanced bio-scaffold devices consist of an intact epithelial basement membrane, naturally derived bioactive molecules and multiple collagen types known to assist the body in the regeneration of new tissues. Commercially branded as MatriStem((R)), UBM can be used in a broad range of regenerative medicine applications. ACell currently has five FDA 510(k) clearances addressing wound care and various surgical indications.
|SOURCE ACell, Inc.|
Copyright©2009 PR Newswire.
All rights reserved